parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.00 from other evidence	0.00
cell type Human Protein Atlas	group enriched in microglia (209 nCPM)	1.00
chemistry Open Targets	hard to drug	0.00
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	1 Parkinson's papers of 43	0.91
pathways Reactome	in no curated pathway	0.00

No case: the score is under the bar. Receipt 12258

ANKHD1 in dopamine neurons, braak+0.00 (p 1.000) → -0.26 (p 0.498)receipt 12265
ANKHD1 in microglia, braak+0.04 (p 0.909) → +0.41 (p 0.269)receipt 12264

receipt 12265: ANKHD1 in dopamine neurons, braak

power: full sample -0.19 (p 0.460, n 18), 95% CI -0.60 to +0.31. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.24 (p 0.337, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.20 (p 0.424, n 18). could be the mix.
skeptic: leave-one-out range -0.33 to -0.10, sign flips 0; without severely affected donors -0.19 (p 0.460, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for ANKHD1 in dopamine neurons.

case closed: nothing better to follow up.

receipt 12264: ANKHD1 in microglia, braak

power: full sample +0.30 (p 0.232, n 18), 95% CI -0.20 to +0.67. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.41 (p 0.089, n 18). does not hold up.
composition: microglia share of nuclei vs axis -0.11 (p 0.652); controlling for it: +0.43 (p 0.077, n 18). could be the mix.
skeptic: leave-one-out range +0.20 to +0.48, sign flips 0; without severely affected donors +0.30 (p 0.232, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for ANKHD1 in microglia.

case closed: nothing better to follow up.

loading the receipts